Clinic
Medemerge LLC
Medemerge LLC was paid $5.40M by Medicaid between Jan 2020 and Nov 2024, across 49 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 45% of everything it billed.
33Billing provider infoMEDEMERGE LLC
GREEN BROOK, NJ 08812
GREEN BROOK, NJ 08812
33aNPI1366656431assigned 05/09/2007
33bProvider typePrimary Care Clinic/Center
28Total paid$5.40M
24GClaims129,861
24DCodes billed49
24AFirst – last monthJan 2020 – Nov 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in New Jersey
Rank by total paid#3 of 130
Median peer was paid$86K
This provider vs. median63×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 16,620 | $777K | |
| 2021 | 30,315 | $1.41M | |
| 2022 | 30,042 | $1.28M | |
| 2023 | 33,429 | $1.17M | |
| 2024incomplete | 19,455 | $770K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 45% | 33,597 | 31,240 | $2.43M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 30% | 30,115 | 28,299 | $1.60M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.3% | 6,678 | 6,073 | $230K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.7% | 3,885 | 3,716 | $143K |
| 93000 | 2.0% | 7,529 | 7,174 | $107K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.9% | 2,908 | 2,523 | $101K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 1.9% | 1,527 | 1,460 | $100K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.6% | 1,352 | 1,327 | $85K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.5% | 1,174 | 1,157 | $79K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 3,610 | 3,270 | $73K |
| 87634 | 1.3% | 2,841 | 2,426 | $70K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.1% | 624 | 585 | $62K |
37 more codes
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.1% | 2,219 | $57K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 493 | $47K |
| 93015 | <1% | 404 | $30K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 2,802 | $29K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,038 | $25K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,572 | $24K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,800 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,747 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,489 | $19K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,169 | $15K |
| 81001 | <1% | 6,255 | $10K | |
| 90686 | <1% | 319 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 169 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 162 | $2K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 489 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 983 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 29 | $1K |
| 90658 | <1% | 56 | $1K | |
| 80061 | Lipid panel | <1% | 14 | $988.78 |
| 84550 | <1% | 29 | $756.00 | |
| 84436 | <1% | 24 | $668.44 | |
| 83615 | <1% | 37 | $610.24 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12 | $587.52 |
| 81000 | <1% | 363 | $483.54 | |
| 84703 | <1% | 80 | $62.26 | |
| 94760 | <1% | 82 | $4.47 | |
| 3014F | 0% | 666 | $0.00 | |
| 3017F | 0% | 1,108 | $0.00 | |
| 3074F | 0% | 505 | $0.00 | |
| 3079F | 0% | 103 | $0.00 | |
| 3044F | 0% | 152 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 19 | $0.00 |
| 3075F | 0% | 42 | $0.00 | |
| 2023F | 0% | 31 | $0.00 | |
| 83721 | 0% | 65 | $0.00 | |
| 3078F | 0% | 476 | $0.00 | |
| 3051F | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBERSHAD, JOSHUA (SENIOR VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Robert Wood Johnson Physician Enterprise | Somerset, NJ | $1.69M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.